US · Healthcare · Biotechnology
EPS came in at -0.62 against a street estimate of -0.64 — a beat of 3.1%.
Analysts rate Kymera Therapeutics Inc a strong buy (17 buy, 3 hold, 0 sell out of 20) with an average price target of $134.71.
CONFIDENT Kymera accelerated KT-621 AD Phase 2b enrollment 6 months ahead, expecting data by year-end 2026. IRF5 program (KT-579) on track for Q4 healthy volunteer data. Cash runway extended to 2029 supports multiple Phase III launches. Q2 2026 BROADEN-2 majority of patients expected from outside U.S.; global site footprint established. Company notes most recent sites for asthma trial exceed AD trial geographic reach. Analysts pressed on baseline severity, placebo response assumptions, pediatric expansion timing, and competitive landscape (STAT6 vs. bispecifics). Management deferred specifics pending data release, emphasized quality execution over speed, and maintained Phase III readiness pending Phase 2b unblinding. Terence Rooney (new CMO) affirmed lupus heterogeneity awareness and careful trial design approach. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 14.07% |
| Baker Bros Advisors LP | 10.41% |
| venBio Select Advisor LLC | 8.99% |
| T. Rowe Price Associates, Inc. | 7.29% |
| Bvf Inc | 6.62% |
| T. Rowe Price Investment Management,Inc. | 6.57% |
| BlackRock Inc | 6.09% |
| Wellington Management Company LLP | 4.42% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 KYMERA THERAPEUTICS, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS Q2 2026 (Period Ended June 30, 2026) --- HEADLINE NUMBERS • Cash & Equivalents: $124. | 2026-08-05 |
| Results announced · Q3 2026 KYMERA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $1.5 billion in cash, cash equivalents and investments as of June 30 | 2026-08-05 |
| Board / officer change · Q3 2026 KYMERA THERAPEUTICS, INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Chief Medical Officer (CMO) Jared Gollob, M.D. resigned effective July 27, 2 | 2026-07-27 |
| Reg FD disclosure · Q2 2026 KYMERA THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Company: Kymera Therapeutics, Inc. (NASDAQ: KYMR), Delaware corporation • Filing Date: Ju | 2026-06-25 |
| Shareholder vote results · Q2 2026 KYMERA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held June 24, 2026 • Company ticker: KYMR, trades on Nasda | 2026-06-24 |
| Quarterly report · Q1 2026 KYMERA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $1,546 million total as of March 31, 2026 (cash $1 | 2026-04-30 |
| Proxy statement · Q2 2026 KYMERA THERAPEUTICS, INC. — 2026 ANNUAL MEETING PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect four Class III directors to s | 2026-04-29 |
| Annual report FY2025 KYMERA THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Kymera Therapeutics, Inc. (NASDAQ: KYMR) • Fiscal year end | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kymera Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.